-+ 0.00%
-+ 0.00%
-+ 0.00%

Taiwan biomedical industry revenue rises 7% in 2025, Sustainable Impact Capital says

PUBT·11/12/2026 10:47:30
Listen to the news
Taiwan biomedical industry revenue rises 7% in 2025, Sustainable Impact Capital says
  • Taiwan's biomedical industry revenue rose approximately 7% to NT$ 830.1 billion in 2025, but commercialization remains a key investment risk.
  • Biotech and healthcare investment reached NT$ 55.08 billion.
  • Policy support in 2026 includes a National Development Fund initiative planning NT$ 10 billion for biomedical industry development over ten years.
  • AI and digital health rank among promising investment areas, provided companies demonstrate genuine clinical demand, clear regulatory pathways and sustainable business models.
  • Licensing assessments should prioritize upfront payments and actual cash proceeds over announced deal values; lengthy development cycles create uncertain exits.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sustainable Impact Capital Co Ltd published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.